Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. - Wikidata - wikimedia - TriplyDB

Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism.

Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism.

http://www.wikidata.org/entity/Q39230043

about

Glial Modulation by N-acylethanolamides in Brain Injury and Neurodegeneration Lipids and Oxidative Stress Associated with Ethanol-Induced Neurological Damage Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity Imaging neuroinflammation in vivo in a neuropathic pain rat model with near-infrared fluorescence and ¹⁹F magnetic resonance α-conotoxin RgIA protects against the development of nerve injury-induced chronic pain and prevents both neuronal and glial derangement The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor Endocannabinoid signalling in innate and adaptive immunity.Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice.Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PPAR-α agonist and effective nutraceutical.Anti-neuropathic effects of Rosmarinus officinalis L. terpenoid fraction: relevance of nicotinic receptors.Mast cells, glia and neuroinflammation: partners in crime?Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines?Endocannabinoids, related compounds and their metabolic routes.The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.An update on PPAR activation by cannabinoids.Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats.Palmitoylethanolamide in the Treatment of Failed Back Surgery Syndrome Delay of morphine tolerance by palmitoylethanolamide.N-Palmitoylethanolamine Supplementation for Long-Lasting, Low-Dosed Morphine Antinociception.A Pharmacological Rationale to Reduce the Incidence of Opioid Induced Tolerance and Hyperalgesia: A Review.

P2860

Q26747533-FB3669D7-7E89-47BF-A5A3-1F60F658AC62 Q26767487-73BFAFF3-5B4A-42FE-9D7B-BB3989D4A244 Q26775847-5D98A30A-6D45-4292-BAC5-80C93E4C20EE Q27305830-FE9B755A-D79F-4C73-A66F-E8065B81EAC4 Q27317567-463CD96E-F94B-4CCA-A012-D704893C3AF8 Q30402093-0C8A02D4-C7A0-440B-B707-2D094186F7C9 Q31122398-D7C136F3-D913-47BA-840B-83F3C0B28313 Q33671206-F856C844-A6DB-4ADA-89E0-7A6519A7CE5F Q34458059-04112F01-ED29-423F-B364-917E34596206 Q35939665-4B5A6584-A68C-4C10-9C45-938A9F36C69F Q37097418-8010B131-6F00-4730-A7B4-3766CB6EB869 Q37319098-BC40EF9E-0B05-4907-B45B-76A1AF01D608 Q38137173-E992B242-BD5C-4741-AA8E-DC80ABD01CF1 Q38246264-9C16FA84-2C97-4B69-9D7B-862247A3DD49 Q38262964-C7998630-D233-4066-B186-E964EF9E6393 Q38600704-CC412CD8-D812-432D-856F-214591E698E4 Q38808034-6994E35B-CEE2-4AE7-87D9-0CFE649C3FFE Q40877659-3998AC79-1E8B-407C-928D-8983D083942E Q41508796-3184918B-83C5-4E9F-A4B6-59C8A4BF0CD5 Q41908176-B28FFF18-0105-4B11-9875-C84C133B8425 Q55094909-8179D7DD-6F08-4EA9-9F8F-D0E99310C089 Q55236616-BC2A7CB2-FE64-499B-B5B9-E19234D2561D

P2860

Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism.

http://www.wikidata.org/entity/Q39230043

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Palmitoylethanolamide is a dis ...... PPAR-alpha-mediated mechanism.

@en

Palmitoylethanolamide is a dis ...... PPAR-alpha-mediated mechanism.

@nl

type

label

Palmitoylethanolamide is a dis ...... PPAR-alpha-mediated mechanism.

@en

Palmitoylethanolamide is a dis ...... PPAR-alpha-mediated mechanism.

@nl

prefLabel

Palmitoylethanolamide is a dis ...... PPAR-alpha-mediated mechanism.

@en

Palmitoylethanolamide is a dis ...... PPAR-alpha-mediated mechanism.

@nl

P1433

Q39230043-20EFE6D7-8268-4DB7-BC7A-E6985CDB1ABE

P1476

Q39230043-B31840B7-67C5-4ECC-ADEE-023BE7E953AB

P2093

Q39230043-297DC8B1-E5A5-4A60-86C0-518D348DC2AA

Q39230043-5153AA9D-B6EB-4157-B1D6-733F3A2EEBA9

Q39230043-B084764E-C4AF-4F4F-9AC3-94B63927A90E

Q39230043-FFC0CF82-1EED-48DC-B1EA-2EA6CD415567

P2860

Q39230043-0D3CEC3E-5C99-447F-9C54-B71F8268DE8F

Q39230043-10265C56-1846-488B-841D-732B8C6E05F5

Q39230043-10497D99-F523-4057-8D25-D09AE5BCC199

Q39230043-168B491D-ACC8-45D2-963F-9F7DCE3C52BE

Q39230043-17B7D7B7-E234-4D7B-81A2-5233824639D5

Q39230043-189B6ED6-CC9C-4B5A-AB33-168ED4A0F943

Q39230043-18E9E59A-E97E-4F1D-9E81-7C3EBF7FB288

Q39230043-1BF7D710-D1A0-48B0-9C7D-F194BD03EFD2

Q39230043-2BE22D41-55D9-472A-9462-BB653AD6D2AE

Q39230043-2D4BD803-AE5B-44AD-B10B-3D5A50811928

P304

Q39230043-0A98243C-B8C4-4290-B6D2-1343995A475F

P31

Q39230043-1836B35F-5649-457C-913C-66AE067671CC

P356

Q39230043-64F3461D-74C9-4C3C-8461-6382C8CFFA08

P478

Q39230043-D6E0FD63-8A49-4B40-8F31-0FE7E7D61682

P50

Q39230043-7FE731FC-12B5-48B9-A2A1-4D0E0D0EE67F

Q39230043-A1906FBA-4801-4ACD-A5D3-631106A827D4

Q39230043-A7D82CE4-E0E9-4CCF-BBD3-5D8944AE4FC0

P577

Q39230043-CF2F54C1-78FC-4DC5-A7BB-96FD68C7F2ED

P5875

Q39230043-F3C60ABE-0093-4554-8B60-52868955262B

P698

Q39230043-1BA34AA0-41F6-4407-BE50-F0F329A80500

P932

Q39230043-87122842-DE67-4616-95FF-142EC7821C8D

P356

P1433

Mediators of Inflammation

P1476

Palmitoylethanolamide is a dis ...... PPAR-alpha-mediated mechanism

@en

P2093

A Pacini

http://www.w3.org/2001/XMLSchema#string

C Ghelardini

http://www.w3.org/2001/XMLSchema#string

M Zanardelli

http://www.w3.org/2001/XMLSchema#string

R Russo

http://www.w3.org/2001/XMLSchema#string

P2860

Peroxisomal disorders: the single peroxisomal enzyme deficiencies

Peroxisome biogenesis disorders

The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice

Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease

Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-α

Mechanisms of Disease: neuropathic pain—a clinical perspective

Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord

Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide.

Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms.

The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide.

P304

328797

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2013/328797

http://www.w3.org/2001/XMLSchema#string

P478

2013

http://www.w3.org/2001/XMLSchema#string

P50

Lorenzo Di Cesare Mannelli

Antonio Calignano

Giuseppe D'Agostino

P577

2013-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236084839

http://www.w3.org/2001/XMLSchema#string

P698

23533304

http://www.w3.org/2001/XMLSchema#string

P932

3596927

http://www.w3.org/2001/XMLSchema#string